A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive 1

Droplet Digital PCR 2

3 **Authors:**

- 4 Fang Wang 1,2, Umar Pervaiz 1#, Hongwei Tian3#, Algahdary Omar Ahmed Omar
- Mariam1, Mahasin Abdallah Mohammed Hamid1, Degui Wang1,2* 5
- 6

7 **Affiliations:**

- 1. School of Basic Medical Sciences, Lanzhou University, Lanzhou, China 8
- 9 2. Center of Medical Experiment, School of Medicine, Lanzhou University, Lanzhou,
- 10 China
- 3. Department of General Surgery, Gansu Provincial People's Hospital 11
- 12
- Keywords: Primer, Probe, SARS-CoV-2, 2019-nCov, droplet digital PCR 13
- 14

15 **Contact information: * Correspondence:**

- **Degui Wang, Professor** 16
- 17 School of Basic Medical Sciences
- 18 Lanzhou University
- 199 DongGang West Road 19
- E-mail: wangdegui@lzu.edu.cn 20
- 21

22 Abstract

- 23
- 24 Background

25 The current increase in the spread of (SARS-CoV-2) critically needs a multitarget 26 diagnostic assays to promote analytical sensitivity to facilitate the public health actions. 27

- 28
- Objective 29

30 The aim of this study was to develop a new primer-probe set targeting N gene of

- SARS-CoV-2 to improve the sensitivity for detection of COVID-19 (Corona Virus 31
- 32 Disease 2019) in multiplex rRT-PCR (Reverse transcript Realtime PCR) and ddPCR
- 33 (Droplet Digital PCR).
- 34
- 35 Results

36 We designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and

37 proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was

105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate 38 39 was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that 40 of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new 41 primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did 42 43 one-step ddPCR for detection the same serial dilution of RNA template. It shows good linearity for primer/probe sets N(LZU3). The calculated lower limit of detection 44 (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul. 45

46

47 Conclusion

The novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both
used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had
higer sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2
detection efficiency in low virus load and asymptomatic infection.

52

53 1. Introduction

54

55 Coronaviruses (CoVs) are one of the largest class of RNA associated viruses that are 56 responsible for infectious disorders in human beings and mammals, the word 57 Coronavirus derived from Latin the meaning is crown. Coronaviruses belong from the Coronaviriade family that has a positive-sense single-stranded RNA genome. It 58 comprises a sizeable genome range between 26 to 32 kilobases; they have a 59 60 club-shaped structure under electron microscopy. According to the distinctive genomic sequences, the Coronavirinae subfamily is divided into four leading 61 subgroups: Alpha, Beta, Gamma, and Delta, coronaviruses^[1, 2]. Previously, almost six 62 human pathogenic coronaviruses were identified. The Novel Coronavirus 63 64 SARS-CoV-2 is highly pathogenic that is caused by severe acute respiratory syndrome coronavirus 2 (COVID-19). The genome sequences have revealed that 65 SARS-CoV-2 is closely related to SARS-CoV, it showed more than 80% similarity 66 with the genomes of other bat derived coronaviruses^[1, 2]. 67

68

In the interest of people's health in January 2020, the WHO announced the pandemic of COVID-19 a Public Health Emergency of International Concern and counseled the countries with poor health systems^[3]. According to the COVID-19 situational report 209, by 16 August 2020, coronavirus disease has spread globally in 216 countries or territories with 21 294 845 confirmed cases and 761 779 confirmed deaths^[4].

74

The COVID-19 affected individuals can be symptomatic or asymptomatic, in the symptomatic host's clinical manifestations are visible, but there is a lack of clinical signs in asymptomatic hosts^[5, 6]. However the early recognition of SARS-CoV-2 is difficult because its general manifestations are similar to other atypical pneumonia,

the capability to verify or clear the suspected client during the worldwide epidemic 79 scenarios is crucial especially when the clinical signs are hard to differentiate^[7]. 80

81

82 At present, there are several tools and tests are suggested by health care authorities for 83 the diagnosis of COVID-19, but previous studies mentioned that molecular diagnosis 84 is a standard and most effective technique to examine rapidly human pathogenic viruses than the CT scan and serological approaches^[8-12]. Moreover, coronaviruses are 85 challenging to cultivate in cell culture and isolation of the pathogenic viruses demand 86 safety level 3 proficiency, which is not accessible in most public health institutions, 87 because of limitations, polymerase chain reaction (PCR) remains the most beneficial 88 laboratory diagnostic test for COVID-19 globally^[13, 14]. 89

90

91 SARS-CoV-2 genome structure was published to promote molecular diagnostic tests, which assist to develop specific sets of primers and probes to detect SARS-CoV-2^[15]. 92 The first assay was released on Jan 23 to target RNA-dependent RNA polymerase 93 (RdRp), envelope (E), and nucleocapsid (N) genes of SARS-CoV-2^[14]. 94

95

96 In the current situation several real-time RT-PCR and reverse transcription-PCR 97 (RT-PCR) assays have been evaluated by using different primers and probes to 98 examine SARS-CoV-2 with safety to decrease the possibility of false laboratory diagnosis^[14, 16, 17]. 99

100

Although Some specific primers and probes have been formulated to target (ORF) 1ab, 101 102 envelop (E) and nucleocapsid (N) gene, but the main issue in the diagnosis of COVID-19 is to increase the detection sensitivity and specificity of SARS-CoV-2^[14, 18, 18] 103 19] 104

105

Previous reports showed that sensitivity of SARS-CoV-2 identification depends on the 106 107 limit of detection (LOD) of designed primers and kit reagents. The RdRP and E genes had notable analytical sensitivity for detection whereas the N gene showed low 108 analytical sensitivity^[13, 19, 20]. The WHO advised to detect at least two different targets 109 from the SARS-CoV-2 genome to diminish the possibility of false results^[19]. 110

111

112 In the present study, we designed the set of primers and probes N(LZU3) targeting N gene of SARS-CoV-2 (LZU3) to developed the quantitative reverse 113 114 transcriptase-polymerase chain reaction (rRT-PCR) and droplet digital polymerase 115 reaction (ddPCR) for the detection and screening of SARS-CoV-2.

116

- 117
- 118 2. Materials and methods
- 119

2.1 SARS-CoV-2 In Vitro Transcribed RNA Reference Material 120

121

122 We used SARS-CoV-2 In Vitro Transcribed RNA Reference Material as the template

in rRT-PCR and ddPCR. This material was purchased from National Institute of 123 Metrology of China (Beijing, China). This reference material was obtained by in vitro 124 transcription of key characteristic genes of SARS-CoV-2, including the nucleoprotein 125 126 N gene (full length), the envelope protein E gene (full length), and the open reading 127 frame1ab (ORF1ab) gene fragment (genomic position: 13201-15600, GenBank

- No.NC_045512). In the material, the copy number of ORF1ab gene was about $9.00\diamond$ 128
- 10^5 copies/µl, and the copy number of N gene was about 7.00×10^5 copies/µl. 129

2.2 Primers and probes 130

Two genes of SARS-CoV-2 were used in rRT-PCR and ddPCR: an open reading 131 132 frame1ab (ORF1ab) gene and nucleoprotein N gene. For targeting ORF1ab gene, we used the primers and probes used in previous research^[21]. For targeting N gene, we 133 used 5 sets of primers/probes, N(CDC) and N(USA) were referred from previous 134 research (Laboratory testing for 2019-nCoV in humans) whereas N(LZU1), N(LZU2) 135 and N(LZU3) were designed by ourselves. The sequences are described in Table 1. 136 Primers and probes were purchased from The Beijing Genomics Institute (Beijing, 137 138 China).

- 139
- 140

Table1 Primers and probes used in rRT-PCR and ddPCR

Name	Sequence(5'-3')
ORF1ab(F)	CCCTGTGGGTTTTACACTTAA
ORF1ab(R)	ACGATTGTGCATCAGCTGA
ODF1ab(Draha)	HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-
ORF1ab(Probe)	BHQ1
N (CDC) (F)	GGGGAACTTCTCCTGCTAGAAT
N (CDC) (R)	CAGACATTTTGCTCTCAAGCTG
N(CDC)(Probe)	FAM-TTGCTGCTGCTTGACAGATT-BHQ1
N (USA) (F)	GACCCCAAAATCAGCGAAAT
N (USA) (R)	TCTGGTTACTGCCAGTTGAATCTG
N(USA)(Probe)	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1

N (LZU1) (F)	CGCGATCAAAACAACGTCG
N (LZU1) (R)	AGGTCTTCCTTGCCATGTTGAG
N (LZU1) (Probe)	HEX-ACTGCGTCTTGGTTCACCGCTCTC-BHQ1
N (LZU2) (F)	CTCAACATGGCAAGGAAGACCT
N (LZU2) (R)	GGTCATCTGGACTGCTATTGGTG
N (LZU2) (Probe)	FAM-CCTCGAGGACAAGGCGTTCCAAT-BHQ1
N (LZU3) (F)	AATGCTGCAATCGTGCTACAA
N (LZU3) (R)	TGATGAGGAACGAGAAGAGGC
N (LZU3) (Probe)	FAM-AGGCTTCTACGCAGAAGGGAGCA-BHQ1

141

2.3 Multiplex rRT-PCR 142

An Applied Biosystems StepOnePlus[™] Real-Time PCR Systems (Applied 143 Biosystems, USA) was used for rRT-PCR. HI Script II U⁺ One Step rRT-PCR Probe 144 Kit (Vazyme Biotech Co., Ltd, Nanjing, China) were used for rRT-PCR. Each 30 µL 145 reaction mixture contained 15 μ L of 2× One-Step U⁺ Mix, 1.5 μ L One-Step U⁺ 146 Enzyme Mix, 0.6µL 50×ROX Reference Dye 1, 0.6µL Gene Specific Primer Forward 147 (10µM),0.6µL of Gene Specific Primer Reverse (10µM), 0.3µL Taqman Probe 148 149 $(10\mu M)$, and 3 μL of total nucleic acid. The final concentrations of primers and probes 150 were 0.2 μ M and 0.1 μ M, respectively. The standard cycling procedure was as follows: 151 reverse transcription at 55°C for 15 min; polymerase activation at 95°C for 30 secs; and 45 cycles of PCR at 95°C for 10 secs and 60°C for 30 secs (signal acquisition). 152 The filter combinations were 465-510 (FAM) and 540-580 (VIC). The Cq values were 153 determined by the automated Fit Points method. 154

155

156 **2.4 Droplet Digital PCR**

For droplet digital PCR, we used the QX200 Droplet Digital PCR System and the 157 One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad). First, we prepared the 158 mixture of reaction, each 20 μ L reaction mixture contained 5 μ L 1× supermix, 2 μ L 159 Reverse Transcriptase (final concentration is 20U/µL), 1µL 300 mM DTT (final 160 concentration is 15 mM), 1.8µL Gene Specific Primer Forward (10µM), 1.8µL of 161 162 Gene Specific Primer Reverse (10µM), 0.5µL Taqman Probe (10µM), and 3 µL of

medRxiv preprint doi: https://doi.org/10.1101/2020.11.03.20224972; this version posted November 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

total nucleic acid. The final concentrations of primers and probes were 900 nM and 163 250 nM, respectively. Secondly, twenty microliters of each reaction mix were 164 converted into droplets with the QX200 droplet generator (Bio-Rad). Thirdly, the 165 droplet-partitioned samples were then carefully transferred to a 96-well plate, sealed 166 167 and cycled in a T100 Thermal Cycler (Bio-Rad) under the following cycling 168 procedure: 50 °C for 60 min (Reverse Transcription), 95 °C for 10 min (Enzyme activation), followed by 40 cycles of 94 °C for 30 s (denaturation) and 55 °C for 1 min 169 (annealing), then 98 °C for 10 min (enzyme deactivation), 4 °C for 30 min (droplet 170 stabilization), and infinite 4-degree hold. Finally, after amplification, the cycled plate 171 was then transferred and read in the FAM and HEX channels using the QX200 reader 172 (Bio-Rad). The absolute copy numbers values were determined by the manual 173 174 threshold line.

175

2.5 Data statistical analysis 176

Analysis of the ddPCR data was performed with Quanta Soft analysis software 177 v.1.7.4.0917 (Bio-Rad) that accompanied the droplet reader to calculate the 178 179 concentration of the target DNA sequences, along with their Poisson-based 95 % 180 confidence intervals. The concentration reported by QuantaSoft equals to the copies of the template per microliter of the final $1 \times ddPCR$ reaction, which was also used in 181 182 all the results. In addition, plots of linear regression were conducted with GraphPad Prism 7.00, and probit analysis for lower limit of detection (LLoD) was conducted 183 184 with StatsDirect software v3.2.9. The LLoD were defined as the lowest concentration at which 95 % of positive samples were detected. 185

- 186
- 187 **3.Results**
- 188

189 **3.1 One-step rRT-PCR reagents and probe chemistries**

Simplex rRT-PCR with different set of primers/probe was performed using a synthetic 190 standard RNA transcript with about 90000 copies/µl for ORF1ab and 70000 copies/µl 191 for N gene as the rRT-PCR template. Each experiment was performed in duplicate. 192 We compared the amplification efficiency and the average Ct values for target 193 ORF1ab, N(CDC), N(USA1), N(LZU1), N(LZU2) and N(LZU3). The average Ct 194 values and standard deviations (SD) were 23.293 (0.144), 24.113(1.059), 195 25.866(1.769), 23.682(0.399), 24.930(0.028), 25.919(0.039), respectively (data not 196 197 shown). These results showed that the kit, the primers/probe set we designed, as well 198 as the amplification condition, are workable.

199

200 3.2 Limit-of-detection (LOD) of simplex one-step RT-PCR with different set of primers/probes for target N gene 201

In order to investigate which primer/probe set has good amplification for the target 202 gene, the LOD was analyzed using serially diluted synthetic SARS-CoV-2 RNA 203 material (21000, 2100, 210, 105, 52.5, 21 and 2.1 copies/reaction for N gene). The Cq 204 values, detection rates, slope, Y-intercept, R², efficiency, and LOD with 95% detection 205 probability are shown in Table 2. The standard curves for each primer/probe set were 206

shown in fig1. Comparing with the N(CDC) and N(USA1), N(LZU3) has the similar 207 Ct value and detection rate in the lower concentration of template, and the slope, 208 Y-intercept, R^2 of N(LZU3) were -3.228, 38.735, and 0.989, respectively (fig 2). The 209 calculated PCR efficiency by machine was 104.093. The detection rate was 100% up 210 to 105 copies/reaction. The calculated lower limit of detection (LOD) with 95% 211 212 detection probability was 118 copies/reaction, which is the almost same as that of N (CDC) (121 copies/reaction) and N (USA1) (119 copies/reaction), suggesting that the 213 prime/probe for N(LZU3) might be another potential primer/probe testing method for 214 target gene N of SARS-CoV-2. 215

216

Table 2 Sensitivity of simplex rRT-PCR with different primer and probe sets for 217 218 N gene

Name	Copies	Ct: Mean	Detecte	Slope	Y-interce	\mathbf{R}^2	Efficienc	LOD with
	/reactio	±SD	d/tested		pt		у	95%
	n		(%)					detection
								probability
ORF1	27000	24.811±	6/6(100	-3.088	39.096	0.996	110.772	122
ab		0.641	%)					Copies/rea
	2700	29.135±	6/6(100					ction
		1.850	%)					
	270	31.493±	12/12(1					
		0.579	00%)					
	135	32.059±	12/12(1					
		0.779	00%)					
	67.5	33.262±1.234	14/18(7					
			7.8%)					
	27	34.473±1.401	12/18(7					
			2.2%)					
	2.7	36.788±1.467	10/18(5					
			5.5%)					
N(CD	21000	24.283±0.592	6/6(100	-2.915	37.798	0.986	120.29	121
C)			%)					Copies/rea
	2100	29.599±0.887	6/6(100					ction
			%)					
	210	31.101±0.649	12/12(1					
			00%)					
	105	31.819±0.631	11/12(9					
			1.7%)					
	52.5	31.827±0.779	14/18(7					
			7.8%)					
	21	33.661±1.264	12/18(7					
			2.2%)					
	2.1	36.973±1.746	10/18(5					
			5.5%)					

N(US	21000	25.769±1.140	6/6(100	-3.173	39.717	0.992	106.6	119
A)		7	%)					Copies/rea
	2100	29.025±1.135	6/6(100					ction
			%)	-				
	210	32.023±0.442	12/12(1					
			00%)	-				
	105	34.124±1.238	11/12(9					
			1.7%)	-				
	52.5	34.497±0.725	15/18(8					
			3.3%)	-				
	21	35.818±2.793	12/18(7					
			2.2%)	-				
	2.1	37.394±2.315	11/18(6					
			1.1%)					
N(LZ	21000	30.551±0.996	6/6(100	-2.984	43.678	0.679	116.332	185
U1)			%)	-				Copies/rea
	2100	33.575±2.213	6/6(100					ction
			%)	-				
	210	35.013±0.921	12/12(1					
	107		00%)	-				
	105	35.474±0.652	10/12(8					
			3.3%)	-				
	52.5	37.948±3.378	12/18(6					
	1	20.014.4.146	6.6%)	-				
	21	38.214±4.146	10/18(5					
	2.1	(negative)	5.5%)					
	2.1	39.738±1.766	10/18(5					
	21000	(negative)	5.5%)	2.055	44.026	0.057	01 710	1.57
N(LZ U2)	21000	28.260±0.994	6/6(100 %)	-3.855	44.936	0.857	81.712	157 Copies/rea
- /	2100	32.345±1.314	6/6(100	-				ction
			%)					
	210	35.4307±0.74	12/12(1	-				
		0	00%)					
	105	37.258	10/12(8	-				
		± 0.740 (negati	3.3%)					
		ve)						
	52.5	38.594±4.146	12/18(6					
		(negative)	6.6%)					
	21	39.152±3.275	4/18(22					
		(negative)	.2%)					
	2.1	41.195±3(neg	2/18(11					
		ative)	.1%)					
N(LZ	21000	24.530±0.354	6/6(100	-3.228	38.735	0.989	104.093	118

U3)			%)
00)	2100	27.676±0.429	6/6(100
			%)
	210	31.848±0.418	12/12(1
			00%)
	105	32.563±0.195	11/12(9
			1.7%)
	52.5	33.835±0.538	15/18(8
			3.3%)
	21	33.763±1.257	14/18(7
			7.7%)
	2.1	37.37±0.539	10/18(5
			5.5%)

219

220 3.3 Detection of SARS-CoV-2 invitro transcribed RNA reference material with 221 **ddPCR**

222 In order to investigate the detection efficiency of ddPCR on SARS-CoV-2, serial dilutions of a SARS-CoV-2 invitro transcribed RNA reference material (27000, 2700, 223 270, 135, 67.5, 27, 2.7 copies/reaction for ORF1ab gene and 21000, 2100, 210, 105, 224 52.5, 21, 2.1 copies/reaction for N gene) were tested with primers/probe sets ORF1ab, 225 226 N (CDC), N(USA) and N(LZU3), the sequence can be seen in table 1. The ddPCR results were analyzed with Quanta software using a manual threshold to define the 227 228 positive and negative droplets, the total events are above 15000 for each sample (data 229 not shown), which make the statistics reasonable, and the positive and negative 230 droplets could be distinctively separated (fig 3).

231

232 Linear regression was analyzed according to the mean measured quantity for each primer/probe sets. In figure 4, It shows good linearity for primer/probe sets ORF1ab, 233 234 N(CDC), N(USA) and N(LZU3), (R2: 0.9917 ,0.9886, 0.9978 and 0.9863, respectively). The reportable range of ddPCR is from 2.7copies/reaction to 27000 235 copies/reaction for ORF1ab and from 2.1copies/reaction to 21000 copies/reaction for 236 N primes/probe sets. According to statistics, the Lower limit of detection (LOD) 237 which was defined as the lowest concentration at which 95 % of positive samples 238 were detected for primer/probe sets ORF1ab, N(CDC), N(USA) and N(LZU3) were 239 copies/reaction, 22.7 copies/reaction, 23.1 copies/reaction, 240 21.5 and 22.4

241 copies/reaction, respectively, that are 1.075 copies/µL, 1.135 copies/µL, 1.155 copies/

242 µL, 1.12 copies/µL. In contrast, the LOD with 95% detection probability of rRT-PCR

is from 118 copies/reaction to 121 copies/reaction for both ORF1ab and N 243 primes/probe sets (table 2). Therefore, the ddPCR is more sensitive for samples with a 244 245 low level quantity of samples.

- 246
- 247

Discussion 249

250

248

251 We developed a new primer/probe set N (LZU3) for targeting N gene of SARS-CoV-2 252 for molecular diagnosis of COVID-19 in both rRT-PCR and ddPCR. The sensitivity 253 and specificity of rRT-PCR is affected by various factors, such as the nucleic acid extraction method, the one-step rRT-PCR reagent, and the primer/probe sets. 254 Optimizing protocols are required before using this methodology in diagnostic 255 laboratories ^[19]. There are more asymptomatic infection and mild symptomatic 256 infection in which the virus quantity might be very low, multiplex ddPCR might be 257 much more useful for detecting asymptomatic infection. 258

259

260 We designed three primers/probes sets targeting the N gene of SARS-CoV-2. According to linear regression statistic in rRT-PCR, when the quantity of template 261 was 105 copies/reaction, the detection rate for N(LZU1) and N(LZU2) were 83.3%, 262 while the detection rate for N(LZU3) was 91.7%, which was similar with that of 263 264 N(CDC) and N(USA) (91.7%) (table 2). Most importantly, if the quantity of template 265 was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, however, the mean Ct value of N(LZU1) and N(LZU2) were above 37, which would be assumed to 266 267 be negative (table 2). For another hand, when we use N(LZU3) in ddPCR, it also showed good linearity with LOD at 22.4 copies/reaction. These result suggested that 268 269 N (LZU3) might be another potential primer/probe set for detection of the SARS-CoV-2. Since the N (LZU3) target the different fragment N gene from N(CDC) 270 271 and N(USA), these three primers/probe sets could be combine used in detection which 272 may ensure multiplex rRT-PCR methodology highly sensitive for detection of 273 SARS-CoV-2.

274

275

276 We also demonstrated that ddPCR had better sensitivity with lower LOD than rRT-PCR. We chose different primer/probe sets N (CDC), N (USA) and N (LZU3) for 277 rRT-PCR, we found that the detection efficiency for low quantity of RNA template 278 (lower than 52.5 copies/reaction) were limited (lower than 85%). The LOD with 95% 279 detection probability for rRT-PCR was above 100 copies/reaction, which is 33.3 280 281 copies/ul. In this scenario we used one-step ddPCR to detect the same serial dilution 282 of RNA template. The LOD with 95% detection probability for ddPCR was about 20 283 copies/reaction, which is about 1 copy/ul, which was 5 times lower than rRT-PCR 284 These results confirmed that the ddPCR is more sensitive for low level quantity of sample which is similar to previously reported results.^[22, 23]. Moreover, the Biorad 285 Company had investigated new kit (The Bio-Rad SARS-CoV-2 ddPCR Test) for 286 detecting 2019-nCoV_N1, 2019-nCoV_N2, and Human RPP30 genes using Droplet 287 Digital PCR. In the kit, the LoD for the samples extracted with the QIAamp Viral 288 289 RNA Mini kit was also 625 cp/mL for N1 and N2, which were similar to our results. 290

In order to improve the detection sensitivity and specificity of SARS-CoV-2, at least 291

medRxiv preprint doi: https://doi.org/10.1101/2020.11.03.20224972; this version posted November 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

two pairs of primer/probe sets were recommended for multiplex rRT-PCR or ddPCR. 292 Our research demonstrated a pair of new primer/probe set for targeting N gene of 293 SARS-CoV-2, which would be provide a complementary for multiplex detection of 294 295 SARS-CoV-2.

296

297 Comparing with the suggested methods (rRT-qPCR. next generation sequencing (NGS), and immunological detection of IgM and IgG) for detection of SARS-CoV-2, 298 ddPCR had several advantages. First of all, nucleic acid detecting is the most direct 299 way to demonstrate the presence of the virus. Secondly, ddPCR may be more proper 300 in which nucleic acid detection is the most direct way to demonstrate the presence of 301 the virus ^[24], it could achieve absolute quantification of SARS-CoV-2 without the 302 standard curve^[24]. Thirdly, through detection within portioned droplets, ddPCR is 303 much more sensitive ^[25] and accurate^[26] in portioned droplets detection, which is 304 might be a strong tool for the detection of very low viral load in mild symptomatic 305 and asymptomatic infection, it is also suitable for monitoring the change of the viral 306 load in the convalescent patients^[27]. Fifthly, ddPCR has a good tolerance for PCR 307 inhibitory substances that might exist in the sample and reaction, therefore improve 308 the detecting efficiency^[28]. An additional advantage of ddPCR is that it can provide 309 high concordance between sites, runs and operators^[26, 29, 30]. However, it is not 310 possible to compare Ct values on different runs or different machines. Thus, the 311 312 established digital PCR method in this study with primer/probe N(LZU3) could be a 313 powerful complementary method for detecting SARS-CoV-2.

314

315 The only limitation of the assay is the lack of clinical samples which required 316 biosafety level 3 laboratory, however in future with the building of P3 facility, we will continue our work on ddPCR detection of SARS-CoV-2. 317

318

Conclusion 319

320 We developed another potential primer/probe set targeting N gene for the detection of SARS-CoV-2, it could be used in both rRT-PCR and ddPCR. It can be combined with 321 ORF1ab, N(CDC) or N(USA) in multiplex rRT-PCR and ddPCR. By using these 322 primer/probe sets we have compared the analytical performance of rRT-PCR and 323 ddPCR, we found that ddPCR could significantly improve the sensitivity of detection, 324 which might be useful in detecting very low viral load in mild symptomatic and 325 326 asymptomatic infection of COVID-19. Furthermore, it is also suitable for monitoring 327 the change of the viral load in the convalescent patients.

- 328
- **Financial Support:** 329

330	This	work	was	supported	by	National	Natural	Science	Foundation	of	China
331	(819	902364),	Special Fu	undi	ng for Ope	en and Sha	ared Large	e-Scale Instru	imei	nts and

- Equipments University (LZU-GXJJ-2019C011 332 of Lanzhou and)
- the Fundamental Research Funds for the Central Universities(lzujbky-2020-sp16). 333

334 335 336		ration of interests Vang, Umar Pervaiz and Hongwei Tian contributed equally to this work.
337 338 339		
340 341	Refere	ence:
342	1.	Valencia DN: Brief Review on COVID-19: The 2020 Pandemic Caused by
343		SARS-CoV-2. <i>Cureus</i> 2020, 12 (3):e7386.
344	2.	Wang H, Li X, Li T, Zhang S, Wang L, Wu X, Liu J: The genetic sequence, origin, and
345		diagnosis of SARS-CoV-2. European journal of clinical microbiology & infectious
346		diseases : official publication of the European Society of Clinical Microbiology 2020.
347	3.	Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R:
348		World Health Organization declares global emergency: A review of the 2019 novel
349		coronavirus (COVID-19). International journal of surgery 2020, 76:71-76.
350	4.	<20200816-covid-19-sitrep-209.pdf>.
351	5.	Sharma R, Agarwal M, Gupta M, Somendra S, Saxena SK: Clinical Characteristics
352		and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19).
353		2020:55-70.
354	6.	Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, Chen
355		H, Mubareka S, Gubbay JB, Chan WCW: Diagnosing COVID-19: The Disease and
356		Tools for Detection. 2020, 14(4):3822-3835.
357	7.	Pfefferle S, Reucher S, Nörz D, Lütgehetmann M: Evaluation of a quantitative
358		RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a
359		high throughput system. Euro surveillance : bulletin Europeen sur les maladies

360 transmissibles = European communicable disease bulletin 2020, 25(9). 361 8. Hecht LS, Jurado-Jimenez A, Hess M, Halas HE, Bochenek G, Mohammed H, 362 Alzahrani F, Asiri MO, Hasan R, Alamri A et al. Verification and diagnostic evaluation 363 of the RealStar((R)) Middle East respiratory syndrome coronavirus (N gene) reverse 364 transcription-PCR kit 1.0. Future microbiology 2019, 14:941-948. 9. Hong TC, Mai QL, Cuong DV, Parida M, Minekawa H, Notomi T, Hasebe F, Morita K: 365 366 Development and evaluation of a novel loop-mediated isothermal amplification 367 method for rapid detection of severe acute respiratory syndrome coronavirus. Journal 368 of clinical microbiology 2004, 42(5):1956-1961. 369 10. Balboni A, Gallina L, Palladini A, Prosperi S, Battilani M: A real-time PCR assay for bat 370 SARS-like coronavirus detection and its application to Italian greater horseshoe bat 371 faecal sample surveys. TheScientificWorldJournal 2012, 2012:989514. 372 Schwartz SL, Lowen AC: Droplet digital PCR: A novel method for detection of 11. 373 influenza virus defective interfering particles. Journal of virological methods 2016, 374 **237**:159-165. 375 Hu W, Bai B, Hu Z, Chen Z, An X, Tang L, Yang J, Wang H, Wang H: Development 12. 376 and evaluation of a multitarget real-time Tagman reverse transcription-PCR assay for 377 detection of the severe acute respiratory syndrome-associated coronavirus and 378 surveillance for an apparently related coronavirus found in masked palm civets. 379 Journal of clinical microbiology 2005, 43(5):2041-2046.

13. LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, Charest H,
381 Desnoyers G, Dust K, Fattouh R *et al*: Real-time PCR-based SARS-CoV-2 detection

382 **in Canadian laboratories**. *Journal of clinical virology : the official publication of the Pan*

383 *American Society for Clinical Virology* 2020, **128**:104433.


- 384 14. Chan JF, Yip CC, To KK: Improved Molecular Diagnosis of COVID-19 by the Novel,
- 385 Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse
- 386 Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. 2020, 58(5).
- 387 15. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y: A new coronavirus
 388 associated with human respiratory disease in China. Nature 2020,

579(7798):265-269.

- 390 16. Nalla AK, Casto AM, Huang MW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu
- H, Jerome KR, Greninger AL: Comparative Performance of SARS-CoV-2 Detection
 Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *Journal of clinical microbiology* 2020, 58(6).
- 394 17. Bordi L, Piralla A, Lalle E, Giardina F, Colavita F, Tallarita M, Sberna G, Novazzi F,
- 395 Meschi S, Castilletti C *et al*. Rapid and sensitive detection of SARS-CoV-2 RNA using
- 396 the Simplexa™ COVID-19 direct assay. Journal of clinical virology : the official
- *publication of the Pan American Society for Clinical Virology* 2020, **128**:104416.
- 398 18. Choudhary ML, Vipat V, Jadhav S, Basu A, Cherian S, Abraham P, Potdar VA:
 399 Development of in vitro transcribed RNA as positive control for laboratory diagnosis of
- 400 SARS-CoV-2 in India. *The Indian journal of medical research* 2020, 151(2 &
 401 3):251-254.
- 402 19. Ishige T, Murata S, Taniguchi T, Miyabe A, Kitamura K, Kawasaki K, Nishimura M,
 403 Igari H, Matsushita K: Highly sensitive detection of SARS-CoV-2 RNA by multiplex

- 404 rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories. *Clinica chimica* 405 *acta; international journal of clinical chemistry* 2020, **507**:139-142.
- 406 20. Wang X, Yao H, Xu X, Zhang P, Zhang M, Shao J, Xiao Y, Wang H: Limits of
- 407 Detection of Six Approved RT-PCR Kits for the Novel SARS-coronavirus-2
- 408 (SARS-CoV-2). *Clinical chemistry* 2020.
- 409 21. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink
- 410 S, Schneider J, Schmidt ML et al. Detection of 2019 novel coronavirus (2019-nCoV)
- 411 by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies
 412 transmissibles = European communicable disease bulletin 2020, 25(3).
- 413 22. Tao Suo XL, Ming Guo, Jiangpeng Feng, Wenjia Hu, Yang Yang, Qiuhan Zhang, Xin
- 414 Wang, Muhanmmad Sajid, Dong Guo, Zhixiang Huang, Liping Deng, Tielong Chen, Fang
- 415 Liu, Xu Ke, Yuan Liu, Qi Zhang, Yingle Liu, Yong Xiong, Guozhong Chen, Yu Chen, Ke
- 416 Lan: ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral
- 417 **load specimens**. *MedRxIv* 2020.
- 418 23. Lianhua Dong JZ, Chunyan Niu, Quanyi Wang, Yang Pan, Xia Wang, Yongzhuo Zhang,
- 419 Jiayi Yang, Manging Liu, Yang Zhao, Tao Peng, Jie Xie, Yunhua Gao, Di Wang, Yun
- 420 Zhao, Xinhua Dai, Xiang Fang: Highly accurate and sensitive diagnostic detection of
- 421 SARS-CoV-2 by digital PCR. *MedRxIv PRE-PRINT* 2020.
- Zhou D, Li Y, Li J, Yu J, Yang H, Wei H: Construction of Lentivirus-Based Reference
 Material for RT-PCR Detection of Middle East Respiratory Syndrome Coronavirus and
 Its Application in External Quality Assessment. *Journal of nanoscience and nanotechnology* 2019, **19**(9):5510-5516.

426 Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Jr., Chun TW, Strain M, Richman 25. 427 D, Luzuriaga K: Absence of detectable HIV-1 viremia after treatment cessation in an 428 infant. The New England journal of medicine 2013, 369(19):1828-1835. 429 Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, 26. 430 Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J et al: International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the 431 432 Measurement of a Rare Sequence Variant. Analytical chemistry 2017, 433 89(3):1724-1733. 434 27. Patterson B, Morrow C, Singh V, Moosa A, Ggada M, Woodward J, Mizrahi V, Bryden 435 W, Call C, Patel S et al. Detection of Mycobacterium tuberculosis bacilli in 436 bio-aerosols from untreated TB patients. Gates open research 2017, 1:11. 437 28. Dingle TC, Sedlak RH, Cook L, Jerome KR: Tolerance of droplet-digital PCR vs 438 real-time quantitative PCR to inhibitory substances. Clinical chemistry 2013, 439 **59**(11):1670-1672. 440 29. Dong L, Wang X, Wang S, Du M, Niu C, Yang J, Li L, Zhang G, Fu B, Gao Y et al. 441 Interlaboratory assessment of droplet digital PCR for quantification of BRAF V600E 442 mutation using a novel DNA reference material. Talanta 2020, 207:120293. 443 30. Whale AS, Jones GM, Pavsic J, Dreo T, Redshaw N, Akyurek S, Akgoz M, Divieto C, 444 Sassi MP, He HJ et al. Assessment of Digital PCR as a Primary Reference Measurement Procedure to Support Advances in Precision Medicine. Clinical 445 446 chemistry 2018, 64(9):1296-1307. 447 448









Figure 1. The standard curve of rRT-PCR using different primer/probe set target 458 459 ORF1ab, N(CDC), N(USA), N(LZU1), N(LZU2), and N(LZU3). These maps were auto generated after amplification and download in the machine software. The mean 460 Slope, Y-intercept, and R2 Efficiency for each primer/probe set were calculated in 461 table 2. Data are representative of three independent experiments with 3 replicates for 462 463 each copy. 464



465

Figure2. Plot of results from a linearity experiment to compare reportable range of
rRT-PCR targeting for N of SARS-CoV-2 with different primer/probe set N(CDC),
N(USA) and N(LZU3). RNA template quantity values (converted to log10) were
plotted on the X axis versus measured Ct values (converted to log10) on the Y axis
using EXCEL software. Data are representative of three independent experiments
with 3 replicates for each concentration.






473

ddPCR result (1D Amplitude) analyzed by 474 Figure 3. The QuantaSoft Version1.7.4.0917. Serial dilution of RNA template was detected with different 475 476 primer/probe sets ORF1ab, N (CDC), N (USA), and N (LZU3). Column A to G means serial dilutions of 27000, 2700, 270, 135, 67.5, 27, and 2.7 copies/reaction for 477 ORF1ab, and 21000, 2100, 210, 105, 52.5, 21and 2.1 copies/reaction for ORF1ab. 478 Column H is represented the negative control (NTC, no template). The dark dots are 479 represented the negative droplets, while the green and blue dots representative the 480 positives droplets in different channels with probe HEX or FAM. The pink line is the 481 manual multi well thresholding. 482

483

484



485

486 Figure 4. Plot of results from a linearity experiment to determine reportable range of ddPCR targeting for ORF1ab and N of SARS-CoV-2 using different primer/probe set. 487 RNA template quantity values (converted to log10) were plotted on the X axis versus 488 measured quantities (converted to log10) on the Y axis using EXCEL software. Data 489 490 are representative of three independent experiments with 3 replicates for each 491 concentration.

Name	Sequence(5'-3')
ORF1ab(F)	CCCTGTGGGTTTTACACTTAA
ORF1ab(R)	ACGATTGTGCATCAGCTGA
	HEX-CCGTCTGCGGTATGTGGAAAGGTTATGG-
ORF1ab(Probe)	BHQ1
N (CDC) (F)	GGGGAACTTCTCCTGCTAGAAT
N (CDC) (R)	CAGACATTTTGCTCTCAAGCTG
N (CDC) (Probe)	FAM-TTGCTGCTGCTTGACAGATT-BHQ1
N (USA) (F)	GACCCCAAAATCAGCGAAAT
N (USA) (R)	TCTGGTTACTGCCAGTTGAATCTG
N(USA)(Probe)	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1
N (LZU1) (F)	CGCGATCAAAACAACGTCG
N (LZU1) (R)	AGGTCTTCCTTGCCATGTTGAG
N (LZU1) (Probe)	HEX-ACTGCGTCTTGGTTCACCGCTCTC-BHQ1
N (LZU2) (F)	CTCAACATGGCAAGGAAGACCT
N (LZU2) (R)	GGTCATCTGGACTGCTATTGGTG
N (LZU2) (Probe)	FAM-CCTCGAGGACAAGGCGTTCCAAT-BHQ1
N (LZU3) (F)	AATGCTGCAATCGTGCTACAA

Table1 Primers and probes used in rRT-PCR and ddPCR

N (LZU3) (R)	TGATGAGGAACGAGAAGAGGC
N (LZU3) (Probe)	FAM-AGGCTTCTACGCAGAAGGGAGCA-BHQ1

N gene Name	Copies /reactio	Ct: Mean ±SD	Detecte d/tested	Slope	Y-interce pt	R ²	Efficienc y	LOD with 95%
	n		(%)					detection probability
ORF1	27000	24.811±	6/6(100	-3.088	39.096	0.996	110.772	122
ab		0.641	%)					Copies/rea
	2700	29.135±	6/6(100					ction
		1.850	%)					
	270	31.493±	12/12(1					
		0.579	00%)					
	135	32.059±	12/12(1					
		0.779	00%)					
	67.5	33.262±1.234	14/18(7					
			7.8%)					
	27	34.473±1.401	12/18(7					
			2.2%)					
	2.7	36.788±1.467	10/18(5					
			5.5%)					
N(CD	21000	24.283±0.592	6/6(100	-2.915	37.798	0.986	120.29	121
C)			%)					Copies/rea
	2100	29.599±0.887	6/6(100					ction
			%)					
	210	31.101±0.649	12/12(1					
			00%)					
	105	31.819±0.631	11/12(9					
			1.7%)					
	52.5	31.827±0.779	14/18(7					
			7.8%)					
	21	33.661±1.264	12/18(7					
			2.2%)					
	2.1	36.973±1.746	10/18(5					
			5.5%)					
N(US	21000	25.769±1.140	6/6(100	-3.173	39.717	0.992	106.6	119
A)		7	%)					Copies/rea
	2100	29.025±1.135	6/6(100					ction
			%)					
	210	32.023±0.442	12/12(1					
			00%)]				
	105	34.124±1.238	11/12(9					
			1.7%)]				
	52.5	34.497±0.725	15/18(8					
			3.3%)					

Table 2 Sensitivity of simplex rRT-PCR with different primer and probe sets for N gene

	21	35.818±2.793	12/18(7					
			2.2%)					
	2.1	37.394±2.315	11/18(6					
			1.1%)					
N(LZ	21000	30.551±0.996	6/6(100	-2.984	43.678	0.679	116.332	185
U1)			%)					Copies/rea
	2100	33.575±2.213	6/6(100					ction
	210	25.012.0.021	%)					
	210	35.013±0.921	12/12(1					
	107	25.474:0.652	00%)					
	105	35.474±0.652	10/12(8					
	52.5	27.049.2.279	3.3%)					
	52.5	37.948±3.378	12/18(6					
	21	38.214±4.146	6.6%)					
	21	(negative)	10/18(5 5.5%)					
	2.1	(negative) 39.738±1.766	10/18(5					
	2.1	(negative)	5.5%)					
N(LZ	21000	28.260±0.994	6/6(100	-3.855	44.936	0.857	81.712	157
U2)	21000	20.200±0.774	%)	-5.055	750	0.037	01.712	Copies/rea
02)	2100	32.345±1.314	6/6(100					ction
	2100	52.5 1021.511	%)					• Holl
	210	35.4307±0.74	12/12(1					
		0	00%)					
	105	37.258	10/12(8					
		±0.740(negati	3.3%)					
		ve)						
	52.5	38.594±4.146	12/18(6					
		(negative)	6.6%)					
	21	39.152±3.275	4/18(22					
		(negative)	.2%)					
	2.1	41.195±3(neg	2/18(11					
		ative)	.1%)					
N(LZ	21000	24.530±0.354	6/6(100	-3.228	38.735	0.989	104.093	118
U3)			%)					Copies/rea
	2100	27.676±0.429	6/6(100					ction
			%)					
	210	31.848±0.418	12/12(1					
	105	22 5(2+0.105	00%)					
	105	32.563±0.195	11/12(9					
	50.5	22 025 10 520	1.7%)					
	52.5	33.835±0.538	15/18(8					
	21	22 762 + 1 257	3.3%)	-				
	21	33.763±1.257	14/18(7					

	7.7%)
2.1 37.37±0.539	10/18(5
	5.5%)

